Boehringer Ingelheim and Eli Lilly Receive EC’s Approval of Jardiance (empagliflozin) for the Treatment of Adults with Chronic Kidney Disease
Shots:
- The EC has approved Jardiance for adults with CKD. The approval was based on the P-III trial (EMPA-KIDNEY) evaluating the effect of Jardiance in 6609 adults from 8 countries
- The results showed a significant benefit of empagliflozin in reducing the relative risk of kidney disease progression or cardiovascular death by 28% with an absolute risk reduction of 3.8%, 14% relative risk reduction in hospitalization for any cause with absolute risk reduction (4.4%). The overall safety data was consistent with prior results confirming the well-established safety profile of empagliflozin
- Jardiance, the first SGLT2 inhibitor to show a significant reduction in all-cause hospitalizations. The product is expected to be available as quickly as possible
Ref: Businesswire | Image: Boehringer
Related News:- The US FDA Approves Boehringer Ingelheim’s Jardiance and Synjardy for the Treatment of Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
